health policy

Advancing Health Equity Action

The trajectories of people's lives are often shaped by things that fall outside of their control, having more to do with unearned disadvantages than with their own behaviours or biology. Despite solid evidence and practical policy solutions, systematic differences in health and health outcomes persist both within and between countries. Evidence shows the distribution of power, resources, and wealth along social gradients are causes of these inequities.

Primary Investigator: 
Award Type: 
Year: 
2020

Towards clinical implementation of pharmacogenomics to improve the treatment of people with depression in BC

In Canada, more than 1 in 10 people will suffer a major form of depression at some point in their lives. There are many effective treatments for depression, including drug therapy. Finding a medication that both works and does not cause severe side effects is often a matter of trial-and-error. This may contribute to the high non-adherence rates and, subsequently, to poorer health outcomes and increased costs. An individual’s genetic makeup is thought to be partly related to whether particular drugs work and whether there are side effects with the drug.

Primary Investigator: 
Award Type: 
Year: 
2020

Smart Text Analytic Tools (STAT) for analysis of patient-centred communications to strengthen health systems in BC

Healthcare stakeholders, including health authorities, facilities, pharmaceutical companies and insurers are increasingly acknowledging the importance of big data to enhance understanding of health behaviours and health systems. Existing analytic tools available to navigate the volume of diverse data types at a frequency that can match the speed at which data is generated are in early stages of development, and often lack validation due to limited access to health data.

Primary Investigator: 
Year: 
2017

The real-world effectiveness of hepatitis C virus (HCV) treatment on decompensated cirrhosis and hospitalizations

Between 230,000 to 450,000 Canadians are infected with hepatitis C virus (HCV). Most of these people were infected decades ago and remained untreated due to the severe side effects and low effectiveness of interferon-based treatment regimens. Therefore, HCV associated liver related morbidity and mortality are now on the rise, with substantial impact on health care utilization. 

Primary Investigator: 
Award Type: 
Year: 
2017

Shared decision-making at the end of life: Including the voices of people with dementia


Recent debates about palliative end-of-life (EOL) care and legalized assisted dying have stimulated new questions about EOL care for those living with dementia. However, when discussing preferences for EOL care, individuals with dementia are often excluded from the decision-making process, leaving decision making to family members and/or care providers. 

Primary Investigator: 
Award Type: 
Year: 
2017

Incentivizing the delivery of sustainable care of chronic diseases in Canada: Case studies in musculoskeletal disease

Concerns about the sustainability of publicly funded health systems and the rising cost of care abound, yet there is little research that explores health care efficiency. Simple cost-saving exercises (i.e. cutting services) may risk harming patients, while more sophisticated, efficiency-saving approaches aim to provide health care at a greater benefit per unit of cost. Encouraging quality and value of health care delivery, whilst reducing waste, is also an indirect way to control health care costs.

Primary Investigator: 
Award Type: 
Year: 
2017

Impact of the BC Influenza Prevention Policy

In 2012, BC became the first province in Canada to implement a province-wide condition-of-service influenza prevention policy (henceforth “the policy”), including the requirement that health care workers either receive the seasonal influenza vaccine or wear a mask while in patient care areas for the duration of the influenza season. A research team that includes representation from the five regional Health Authorities, the BC Centre for Disease Control, Providence Health Care) and the Provincial Health Services Authority will evaluate the effectiveness of the policy in BC.

Year: 
2015

Addressing disparities in access to living donor kidney transplantation in South and East Asian Canadians

Kidney Transplantation is the treatment of choice for patients with end stage kidney disease. Living donor kidney transplantation ensures the timeliest transplant and offers the best post-transplant survival, making it the gold standard therapy for patients with kidney failure. Unfortunately, access to living donor kidney transplantation varies by age, socioeconomic status, and race. However, our understanding of these disparities are severely limited, particularly in Canada - therefore strategies to address these issues remain poorly characterized.

Primary Investigator: 
Award Type: 
Year: 
2014

Investigating pharmaceutical policies, coverage, and costs

Prescription medicines play a key role in the treatment and prevention of disease, as evidenced by the fact they are the second-largest and fastest-growing component of health care expenditures in British Columbia. Dr. Michael Law's research program includes studies on the broad themes of pharmaceutical policies, coverage, and costs. Pharmaceutical Policies. In January 2009, a policy change in British Columbia gave pharmacists the authority to independently modify and renew prescriptions.

Primary Investigator: 
Award Type: 
Year: 
2011
Subscribe to RSS - health policy